Development and Validation of UV Spectrophotometric methods for simultaneous estimation of Lobeglitazone Sulfate and Glimepiride in combined dosage form
DOI:
https://doi.org/10.22456/2527-2616.140749Keywords:
Lobeglitazone sulfate, Glimepiride, Simultaneous equation method, Second order derivative spectrophotometry, ValidationAbstract
Two UV spectrophotometric methods have been developed for accurately analyzing Lobeglitazone Sulfate and Glimepiride in combined dosage form, used in the treatment of type 2 diabetes mellitus. Method I, known as the simultaneous equation method (Vierodt’s Method), relies on measuring the absorption at 250 nm for Lobeglitazone Sulfate and 227 nm for Glimepiride, their respective λmax values. Method II involves the second-order derivative method, where the absorbance of Lobeglitazone Sulfate is measured at 297 nm (zero-crossing point of Glimepiride), and that of Glimepiride is measured at 259 nm (zero-crossing point of Lobeglitazone Sulfate). Both methods exhibit linearity within specified concentration ranges: 3-13 μg/mL for Lobeglitazone Sulfate and 6-26 μg/mL for Glimepiride, using methanol as the solvent. The accuracy of these methods was confirmed through recovery studies, yielding results within the range of 98-102% for both drugs. Precision was evaluated through repeatability and intermediate precision studies, demonstrating % RSD values below 2%, indicating high precision. A comparison between the two methods using the F-test showed no significant difference. Statistical validation according to ICH Q2 R1 guideline confirmed the reliability of the results obtained from both methods.
Downloads
References
“Lobeglitazone sulfate” accessed on March 2023, https://go.drugbank.com/salts/DBSALT002555.
National Center for Biotechnology Information “PubChem Compound Summary for CID 15951505, Lobeglitazone sulfate” accessed on March 2023, https://pubchem.ncbi.nlm.nih.gov/compound/Lobeglit azone-sulfate.
“Glimepiride” accessed on March 2023, https://go.drugbank.com/drugs/DB00222.
National Center for Biotechnology Information “PubChem Compound Summary for CID 3476, Glimepiride.” accessed on March 2023, https://pubchem.ncbi.nlm.nih.gov/compound/3476.
“Lobeglitazone Sulfate + Glimepiride” accessed on March 2023, https://www.1mg.com/generics/lobeglitazone-sulfateglimepiride510350#:~:text=Lobeglitazone%20Sulfate%2BGlime piride%20is%20used,of%20type%202%20diabetes%2 0mellitus.&text=Lobeglitazone%20Sulfate%20%2B% 20Glimepiride%20contains%20two%20antidiabetic% 20ingredients.
“Lobg G 1 Tablet” accessed on March 2023, https://www.1mg.com/drugs/lobg-g-1-tablet 943770?wpsrc=Google+Organic+Search.
Gulhane PD, and Jawarkar SG, “Bioanalytical method development and validation for determination of lobeglitazone in human plasma” Int. Res. J. Mod. Eng. Technol. Sci. 2023, 05.
Lee JH, Woo YA, Hwang IC, Kim CY, Kim DD, et al. “Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.” J Pharm Biomed Anal. 2009.
Indian Pharmacopoeia, Government of India, Ministry of Health and Family Welfare, Published by The Indian Pharmacopoeia Commission, Ghaziabad, 2023, Vol. I, pp 1172-1174.
United State Pharmacopoeia 31 National Formulary 26, The United State Pharmacopeial Convection, Rockville, 2023, Vol. II.
British Pharmacopoeia. Her Majesty’s Stationery Office, London, 2023, Vol. II.
European Pharmacopoeia. Council of Europe, Star Bourg Cedex, France, 2022, Vol II.
Altinöz S, and Tekeli D. “Analysis of glimepiride by using derivative UV spectrophotometric method.” J Pharm Biomed Anal. 2001, 24(3), 507-515.
Maslarska V, “Development, estimation and validation of Glimepiride in pharmaceutical formulation by HPLC method” International Journal of Pharma Sciences and Research, IJPSR, 2014, 05, 3198-3195.
Khaldoon S, Alhadad HNK, and Salman AL, “Development of an RP-HPLC Method to estimation Glimepiride in Bulk and Solid Dosage Form.” J Popl Ther Clin Pharmacol. 2023.
Mahmoud MS, El-Adl, SM, Baraka MM and Hassan AA, “Rapid RP-HPLC Method for Simultaneous Estimation of Metformin, Pioglitazone, and Glimepiride in Human Plasma” AK Journal, 2020, pp 16-21.
Kande T, Barge V, Bhosale A, and Khatal S, “Development and validation of analytical methods for simultaneous estimation of Pioglitazone and Glimepiride in bulk and pharmaceutical dosage form by using RP-HPLC method” Int. J. Curr. Adv. Res. 2019, 8, 20124-20129.
Gaikwad S, Kavale L, Bhirud N, Bebi R, Girawale N, et al. “Method devlopment and validation of Metformn and Glimepiride in tablet dosage form by RP-HPLC method” World J. Pharm. Res. 2014, 3(9),769-779.
Neelima K, and Prasad YR, “Analytical Method Development and Validation of Metformin, Voglibose, Glimepiride in Bulk and Combined Tablet Dosage Form by Gradient RP-HPLC” J. qual. res. rev. ext. 2014, 05, 27-33.
Strugaru AM, Kazakova J, Butnaru E, Caba IC, and Torres RF, “Simultaneous determination of Metformin and Glimepiride in human serum by ultra-high performance liquid chromatography quadrupole time of flight Mass spectrometry detection” J Pharm Biomed Anal. 2018, 1-23.
Shaikh SS, and Dighe NS, “Simultaneous estimation of pioglitazone, glimepiride & metformin hydrochloride in bulk & tablet dosage form by UV, RP-HPLC method” J Pharm Chem Anal. 2021, 8(3), 91-99.
Bonfilio R, Peres C, and Salgado Hérida R N, “Multivariate Development and Validation of a Stability-Indicating HPLC Method for the Determination of Glimepiride in Tablets,” Journal of AOAC INTERNATIONAL, 2013, 96(5), 960–967.
Shaik M, Viswanadhapalli M, Pasupuleti S, and Shaik R, “Analytical Method Development and Validation of Metformin, Losartan and Glimepiride in Bulk and Combined Tablet Dosage form by Gradient RP-HPLC” J. Pharm. Sci. 2017, 16(02), 99-109.
Kottu PK, Gadad AP and Dandagi PM, “Method development and validation for the simultaneous estimation of pioglitazone and glimepiride – a UV Spectrophotometric approach” Indian Drugs, 2012, 49, 30-35.
Navaneethan G, K Karunakaran, and Elango KP, “Simultaneous estimation of Pioglitazone, Glimepiride and Glimepiride impurities in combination drug product by a validated stability- indicating RP-HPLC method” J. Chil. Chem. Soc. 2011, 56, 815-818.
Mohd AB, Sanka K, Gullapelly R, Diwan PV, and Shastri Nalini, “Development and validation of RPHPLC method for glimepiride and its application for a novel self-nanoemulsifying powder (SNEP) formulation analysis and dissolution study” Journal of Analytical Science and Technology, 2014, 1-8.
Marie AA, Hammad SF, Salim MM, Elkhodary MM, and Kamal AH, “Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.” Sci Rep, 2023, 13.
Samala S, Tatipamula SR, and Veeresham C, “Determination of Glimepiride in Rat Serum by RPHPLC Method,” Am. J. Anal. Chem. 2011, 2, 152-157.
Sultana N, Arayne MS, Ali SN, and Zuberi MH, “Simultaneous determination of Glipizide and Glimepride by RP-HPLC in dosage formulations and in human serum.” Med Chem Res. 2012, 21, 2443–2448.
Vaingankar PN and Amin PD, “Development and Validation of Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin HCl and Glimepiride in Fixed-Dose Combination.” Anal Chem Insights. 2016 (13)11, 13-20.
Dhole SM, Khedekar PB, and Amnerkar ND, “Development and Validation of HPTLC Densitometry method for simultaneous estimation of Rosiglitazone and Glimepiride in fixed tablet dosage form.” J. Chil. Chem. Soc. 2013, 58, 1663-1666.
International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use. Validation of analytical procedures: text and methodology Q2(R1). Geneva; 2005.
Downloads
Published
Versions
- 27-03-2026 (2)
- 19-07-2024 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Drug Analytical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Licensing:
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.
